Zoetis (ZTS) Q3 2026 earnings review
Zoetis raises its profit outlook, but U.S. pet sales drop
Zoetis, the world's largest maker of pet and farm animal medicines, leaned on livestock demand and share buybacks to offset shrinking U.S. pet sales. Third-quarter revenue fell 1% to $2.4 billion as U.S. pet treatment sales dropped 8% on rival launches and clinic price discounting. Chief executive Kristin Peck said results matched expectations and raised the full-year per-share profit outlook excluding one-offs, but by our math the plan still leaves fourth-quarter profit falling 27%.
| Sales from businesses owned a year ago | -1% excluding currency; $2.39B reported |
|---|---|
| U.S. companion animal revenue | $980M -8% from a year ago |
| Profit per share, excluding one-offs | $1.75 +3% from a year ago (-5% before buybacks) |
| Full-year profit per share outlook, ex-one-offs | Raised $0.10 to $6.25–6.35; reported EPS cut $0.05 |
⚖️ Verdict: ⚪ Neutral
The story is unchanged because the core U.S. pet medicine business kept shrinking even against an easier comparison from last year. The $0.10 increase in the per-share profit outlook excluding one-offs came from cutting research spending and taxes, while an $89 million write-down on acquired research assets forced a cut to the reported profit plan. On the positive side, global farm animal sales grew 7% excluding currency and divestitures, beating the slower second-half pace management had pointed to.
The question now is whether price discounts and rebates are stabilizing Zoetis's U.S. dermatology clinic share or just lowering profit margins. One view is that temporary launch promotions from rivals will fade once clinics settle on products; the other is that cheaper alternatives have permanently reduced what pet owners will pay. The conference call's U.S. dermatology share reading and fourth-quarter gross margin will tell.
🐂 Bull Case
Livestock and International Cushion the Pet Slowdown
"Continued pressure in Companion Animal was partially offset by growth in Livestock and Diagnostics, reflecting the breadth of our portfolio," chief executive Kristin Peck said. Zoetis sells medicines for farm animals alongside pet treatments, and management relies on farm demand and overseas clinics to steady the business while U.S. pet sales shrink.
Farm animal sales grew 7% from businesses owned a year ago excluding currency, cooling from 11% in the second quarter as temporary U.S. demand faded, but beating the 5% pace management had pointed to for the second half.
- International farm animal revenue: $531 million, up 9% from a year ago excluding currency and divestitures
- U.S. farm animal revenue: $266 million, up 5% on cattle, swine and poultry demand
- Fish products: $98 million, up 18% excluding currency
- International gross margin: 68.9%, up 0.7 percentage points from a year ago
The international margin gain matters because farm products usually carry lower margins than pet medicines. Holding overseas operating expenses flat at $169 million allowed Zoetis to grow international pre-tax profit by 7% to $600 million.
What to watch: fourth-quarter international revenue growth against last year's elevated base, when overseas customers ordered early ahead of an accounting calendar change. Holding growth positive would show overseas demand can absorb the comparison.
Buybacks and Research Cuts Lift Per-Share Profit
Zoetis has been buying back its own stock and trimming spending to protect per-share earnings while revenue declines. Critics argue that borrowing money to buy shares during an earnings downturn misallocates capital, while supporters say high margins justify retiring stock.
In the third quarter, profit excluding one-offs fell 5% to $720 million, but diluted share count dropped 7.1% from a year ago to 411.6 million. That lower share count turned the profit drop into a 3% gain in per-share profit excluding one-offs, to $1.75.
Zoetis also raised its full-year per-share profit outlook by $0.10 at the middle of the range, to $6.25–$6.35. The increase comes from cutting the full-year research and development plan by $15 million and lowering the expected tax rate by half a percentage point to 20%, rather than from higher product margins.
What to watch: the third-quarter filing's share repurchase table for the dollar amount spent and average price paid in the quarter. Slowing buybacks while debt costs rise would show management is conserving cash for acquisitions.
🐻 Bear Case
U.S. Pet Medicine Drop Continues on Discounts
U.S. companion animal medicines — treatments for dogs, cats and horses — are Zoetis's largest and most profitable business. Chief executive Kristin Peck said the company remains focused on "defending our position" as rivals launch competing skin and parasite drugs and pet owners visit veterinary clinics less often.
U.S. companion animal sales fell 8% from a year ago to $980 million, after falling 11% in both the first and second quarters. Zoetis attributed the drop to "macro-driven price sensitivity and competitive pressure in dermatology, as well as generic competition" against older treatments.
The third quarter lapped an easier comparison from a year ago, when U.S. pet sales were flat, yet revenue still shrank 8% and international companion animal sales stalled at 0% excluding currency. Defending clinic share with rebates and promotions also pushed U.S. segment gross margin down 1.0 percentage point from a year ago to 82.2%, because cost of sales stayed flat at $222 million while revenue dropped $76 million.
What to watch: U.S. dermatology clinic market share and net price realization on the conference call. Another drop from last quarter's 86% share would show that price discounts are not stopping the customer losses.
Full-Year Plan Leaves a Steep Fourth-Quarter Drop
"Our third-quarter performance was in line with our expectations," Peck said, and Zoetis lifted the bottom of its full-year revenue outlook by $100 million. On the surface, raising the profit outlook after two straight quarterly cuts looks like stabilization.
By our math, Subtracting the first nine months from the full-year outlook leaves a steep drop for the fourth quarter. The plan keeps full-year production costs excluding one-offs at about 29.0% of revenue after they ran at 28.1% for the first nine months.
- Fourth-quarter revenue implied by the outlook: $2,149 million at the middle of the range, down 10% from a year ago
- Fourth-quarter underlying sales implied by the outlook: down about 3% excluding currency and divestitures
- Fourth-quarter profit excluding one-offs implied by the outlook: $473 million, down 27% from $648 million a year ago
- Fourth-quarter cost of sales excluding one-offs implied by the outlook: about 32.0% of revenue, up from 29.0% in the third quarter
Part of the fourth-quarter revenue drop comes from lapping last year's early international orders, but the implied 32.0% cost of sales ratio points to heavier price discounting and unfavorable product mix at year-end.
What to watch: fourth-quarter cost of sales excluding one-offs as a percentage of revenue. A reading near 32% would confirm that promotional rebates are taking a deeper bite out of gross margin entering 2027.
Pipeline Write-Down and Layoffs Cut Reported Profit
Zoetis excludes acquisition write-downs and restructuring from its headline profit figures, and this quarter the gap between reported profit and profit excluding one-offs widened. Reported net income fell 18% from a year ago to $591 million, while pre-tax margin fell 6.1 percentage points to 30.5%.
Two expense lines drove the drop. Other net deductions rose by 3.5 percentage points of revenue to $72 million, because Zoetis booked $89 million of "impairment charges on in-process research and development assets, acquired from PetMedix in 2023, resulting from updated estimates of development and commercial assumptions". Restructuring charges rose by 1.6 percentage points of revenue to $43 million, including $30 million for "employee termination costs under a comprehensive cost and productivity program".
Because of these charges, Zoetis raised its full-year forecast for one-off items from $150 million to $210 million and cut its reported per-share profit outlook by $0.05, to $5.50–$5.60.
What to watch: which PetMedix antibody drug candidates were written down when the quarterly filing arrives. An impairment on a major pet therapy would weaken the long-term pipeline story.
Risks this quarter didn't answer
Four standing concerns could not be read from the earnings release because Zoetis reports franchise sales, clinic share and legal updates on the conference call or in its quarterly filing.
- U.S. dermatology clinic share: stood at 86% in the second quarter after falling 5 percentage points from the first; the conference call will show whether the newest rival took more share.
- Osteoarthritis pain drug sales: revenue for Librela, its monthly pain injection for dogs, fell in each of the last five quarters; the quarterly filing's product table will give the third-quarter reading.
- Net price realization: management previously warned full-year net prices could fall 1% to 2% due to rebates; the call will update where pricing sits after the third quarter.
- Shareholder lawsuits and finance transition: no update in the release on the May 2026 securities class action or the new chief financial officer's cost savings target.
👓 Other Themes
FDA Approves Dog Antibiotic Ahead of Schedule
In October, the U.S. Food and Drug Administration approved Convenia RTU for Dogs, a ready-to-use antibacterial injection that Zoetis plans to start selling in the first quarter of 2027. The animal health group also said "select approvals anticipated in 2027 now expected in Q4 2026", and it launched Lenivia, a three-month osteoarthritis pain injection for dogs, in Great Britain.
💲 Other KPIs
Net interest expense — the cost of Zoetis's debt after subtracting interest earned on cash — rose 7% from a year ago to $62 million. Across the first nine months of 2026, net interest costs climbed 12% to $185 million after the company issued convertible debt late last year to fund share buybacks.
Selling, general and administrative expenses — the day-to-day overhead of sales teams and corporate offices — stayed flat from a year ago at $582 million on a reported basis and $571 million excluding one-offs. Because total revenue fell 1%, overhead excluding one-offs ticked up from 23.6% of revenue a year ago to 23.9%.
🔮 Guidance
Raised at the low end. Zoetis lifted the bottom of its dollar range by $100 million and narrowed its outlook for sales from businesses owned a year ago excluding currency to a decline of 2% to 1%, from a decline of 3% to 1%. By our math, the middle of the range implies fourth-quarter revenue falls 10% reported and 3% underlying. This small upward move follows two straight cuts of $105 million and $600 million.
Raised. The middle of the range moved up $25 million, calling for profit excluding one-offs to shrink 7% to 5% excluding currency and divestitures, compared with a 9% to 5% drop previously. By our math, the plan leaves $473 million for the fourth quarter at the middle of the range, a 27% drop from a year ago. Prior moves on this outlook were cuts of $90 million and $315 million.
Raised. The animal health company lifted both ends of the range by $0.10, which puts full-year per-share profit excluding one-offs down 1.7% from last year's $6.41 at the middle of the range. By our math, subtracting $5.14 earned in the first nine months leaves $1.16 for the fourth quarter, down 22% from $1.48 a year ago. The $0.10 raise follows cuts of $0.125 and $0.725.
Cut. Zoetis lowered its reported per-share profit outlook by $0.05 at both ends, pointing to an 8% drop for the year at the middle of the range. By our math, that leaves $1.04 per share in the fourth quarter, down 24% from $1.37 a year ago. Management cut the range because third-quarter asset write-downs and layoffs outweighed the operational tax and research savings.
Unchanged at the middle of the range. The US group narrowed its overhead spending plan by $10 million on each side, keeping the midpoint at $2,355 million, or 0.5% above last year. By our math, that leaves $613 million of overhead for the fourth quarter, flat against $615 million in the fourth quarter of 2025.
Cut. Management lowered planned research spending by $15 million across the range, leaving full-year research costs up 2% from 2025 at the middle of the range. By our math, after spending $526 million in the first nine months, the plan leaves $184 million for the fourth quarter, down 8% from $199 million a year ago.
Cut. The expected full-year tax rate on profit excluding one-offs dropped by half a percentage point to 20%, after the third-quarter rate came in at 19.6%. That half-point reduction adds about $16 million to full-year profit excluding one-offs.
Raised. Zoetis increased its forecast for pre-tax one-off charges by $60 million, the third straight increase after starting the year at $65 million and moving to $100 million and $150 million. Having already booked $247 million of these charges in the first nine months, the $210 million full-year figure implies a net credit or tax-adjusted figure in the fourth quarter.
❓ Key Questions
Where did U.S. dermatology clinic share land in Q3?
In the second quarter, Zoetis held 86% of U.S. clinic share in dermatology, down 5 percentage points from the first quarter as a new competitor launched. The release did not give the third-quarter share or say when rebate spending might ease.
Which PetMedix drug programs took the $89 million write-down?
Zoetis bought PetMedix in 2023 to build antibody therapies for pets and wrote down $89 million of its research assets this quarter after changing commercial assumptions. Investors need to know which pipeline candidates were impaired.
Which 2027 product approvals moved into the fourth quarter?
The release stated that select approvals previously expected in 2027 are now anticipated in the fourth quarter of 2026. Naming the products and markets will show whether long-acting Cytopoint or another major pet medicine is ahead of schedule.
Why does the outlook imply a 32% fourth-quarter cost ratio?
Cost of sales excluding one-offs ran at 28.1% of revenue for the first nine months, yet Zoetis kept its full-year target at 29.0%. By our math, that requires fourth-quarter production costs to reach 32.0% of revenue.